TY - JOUR
T1 - Low tristetraprolin expression is associated with lethal prostate cancer
AU - Gerke, Travis
AU - Beltran, Himisha
AU - Wang, Xiaodong
AU - Lee, Gwo Shu Mary
AU - Sboner, Andrea
AU - Karnes, R. Jeffrey
AU - Klein, Eric A.
AU - Davicioni, Elai
AU - Yousefi, Kasra
AU - Ross, Ashley E.
AU - Bornigen, Daniela
AU - Huttenhower, Curtis
AU - Mucci, Lorelei A.
AU - Trock, Bruce J.
AU - Sweeney, Christopher J.
N1 - Funding Information:
R.J. Karnes reports receiving a commercial research grant from GenomeDx; has ownership interest (including stock, patents, etc.) in GenomeDx. E. Davicioni is a Chief Scientific Officer at GenomeDx, Inc. K. Yousefi and A.E. Ross have ownership interest (including stock, patents, etc.) in GenomeDX Biosciences. B.J. Trock reports receiving a commercial research grant from Myriad Genetics, Inc. and MDxHealth, Inc.; is a consultant/advisory board member of Myriad Genetic, Inc. and GenomeDx Biosciences, Inc.; and has provided expert testimony for Rochon Genova LLP. C.J. Sweeney, L.A. Mucci, T. Gerke, G.-S.M. Lee, D. Bo€rnigen, X. Wang and C. Huttenhower have ownership interest (including stock, patents, etc.) in TTP as a biomarker in prostate cancer. C.J. Sweeney has ownership interest (including stock, patents, etc.) in a company developing dimethylaminoparthenolide. No other potential conflicts were disclosed by the other authors.
Funding Information:
The authors are grateful to the participants and staff of the Physicians' Health Study and Health Professionals Follow-Up Study for their valuable contributions, as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. DOD W81XWH-11-1-0379 (to C.J. Sweeney). The Health Professionals Follow-Up Study was supported by U01CA167552 (to L.A. Mucci and Willett). This study was additionally supported by CA136578 (to L.A. Mucci), CA141298 (to C.J. Stampfer), CA131945 (Loda), and P50CA090381 (Kantoff). L.A. Mucci was supported by a Prostate Cancer Foundation Young Investigator Award.
Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2019/3
Y1 - 2019/3
N2 - Background: Inflammation is linked to prostate cancer enzalutamide sensitivity. Men with localized prostate cancer progression and is mediated by NF-kB. Tristetraprolin is a key and lower quartile of tumor tristetraprolin expression had a node of NF-kB activation and we investigated its biological significant, nearly two-fold higher risk of lethal prostate cancer and prognostic role in lethal prostate cancer. after adjusting for known clinical and histologic prognostic Methods: In vitro assays assessed the function of tristetrapro-features (age, RP Gleason score, T-stage). Tristetraprolin lin and the association between low mRNA tristetraprolin levels expression was also significantly lower in mCRPC compared and lethal prostate cancer (metastatic disease or death) was with localized prostate cancer. assessed across independent prostatectomy cohorts: (i) nested Conclusions: Lower levels of tristetraprolin in human pros-case-control studies from Health Professionals Follow-up Study tate cancer prostatectomy tissue are associated with more and Physicians' Health Study, and (ii) prostatectomy samples aggressive prostate cancer and may serve as an actionable from Cleveland Clinic, Mayo Clinic, Johns Hopkins and Memo-prognostic and predictive biomarker. rial Sloan Kettering Cancer Center. Tristetraprolin expression Impact: There is a clear need for improved biomarkers to levels in prostatectomy samples from patients with localized identify patients with localized prostate cancer in need of disease and biopsies of metastatic castration–resistant prostate treatment intensification, such as adjuvant testosterone sup-cancer (mCRPC) were assessed in a Cornell University cohort. pression, or treatment de-intensification, such as active sur-Results: In vitro tristetraprolin expression was inversely veillance. Tristetraprolin levels may serve as informative bio-associated with NF-kB–controlled genes, proliferation, and markers in localized prostate cancer.
AB - Background: Inflammation is linked to prostate cancer enzalutamide sensitivity. Men with localized prostate cancer progression and is mediated by NF-kB. Tristetraprolin is a key and lower quartile of tumor tristetraprolin expression had a node of NF-kB activation and we investigated its biological significant, nearly two-fold higher risk of lethal prostate cancer and prognostic role in lethal prostate cancer. after adjusting for known clinical and histologic prognostic Methods: In vitro assays assessed the function of tristetrapro-features (age, RP Gleason score, T-stage). Tristetraprolin lin and the association between low mRNA tristetraprolin levels expression was also significantly lower in mCRPC compared and lethal prostate cancer (metastatic disease or death) was with localized prostate cancer. assessed across independent prostatectomy cohorts: (i) nested Conclusions: Lower levels of tristetraprolin in human pros-case-control studies from Health Professionals Follow-up Study tate cancer prostatectomy tissue are associated with more and Physicians' Health Study, and (ii) prostatectomy samples aggressive prostate cancer and may serve as an actionable from Cleveland Clinic, Mayo Clinic, Johns Hopkins and Memo-prognostic and predictive biomarker. rial Sloan Kettering Cancer Center. Tristetraprolin expression Impact: There is a clear need for improved biomarkers to levels in prostatectomy samples from patients with localized identify patients with localized prostate cancer in need of disease and biopsies of metastatic castration–resistant prostate treatment intensification, such as adjuvant testosterone sup-cancer (mCRPC) were assessed in a Cornell University cohort. pression, or treatment de-intensification, such as active sur-Results: In vitro tristetraprolin expression was inversely veillance. Tristetraprolin levels may serve as informative bio-associated with NF-kB–controlled genes, proliferation, and markers in localized prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=85062420179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062420179&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-18-0667
DO - 10.1158/1055-9965.EPI-18-0667
M3 - Article
C2 - 30420441
AN - SCOPUS:85062420179
VL - 28
SP - 584
EP - 590
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 3
ER -